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abstract: Many studies estimate that chromosomal mosaicism within the cleavage-stage human embryo is high. However, comparison of
twouniquemethodsofaneuploidyscreeningofblastomereswithinthesameembryohasnotbeenconductedandmayindicatewhethermosaicism
has been overestimated due to technical inconsistency rather than the biological phenomena. The present study investigates the prevalence of
chromosomal abnormality and mosaicism found with two different single cell aneuploidy screening techniques. Thirteen arrested cleavage-
stage embryos were studied. Each was biopsied into individual cells (n ¼ 160). The cells from each embryo were randomized into two groups.
ThosedestinedforFISH-basedaneuploidyscreening(n ¼ 75)wereﬁxed,onecellperslide.CellsforSNPmicroarray-basedaneuploidyscreening
(n ¼ 85) were put into individual tubes. Microarray was signiﬁcantly more reliable (96%) than FISH (83%) for providing an interpretable result
(P ¼ 0.004). Markedly different results were obtained when comparing microarray and FISH results from individual embryos. Mosaicism was sig-
niﬁcantlylesscommonlyobservedbymicroarray(31%)thanbyFISH(100%)(P ¼ 0.0005).AlthoughFISHevaluatedfewerchromosomespercell
and fewer cells per embryo, FISH still displayed signiﬁcantly more unique genetic diagnoses per embryo (3.2+0.2) than microarray (1.3+0.2)
(P , 0.0001).Thisistheﬁrstprospective,randomized,blindedandpairedcomparisonbetweenmicroarrayandFISH-basedaneuploidyscreening.
SNPmicroarray-based24chromosomeaneuploidyscreeningprovidesmorecompleteandconsistentresultsthanFISH.Theseresultsalsosuggest
thatFISHtechnologymayoverestimatethecontributionofmitoticerrortotheoriginofaneuploidyatthecleavagestageofhumanembryogenesis.
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Introduction
TheconceptofaneuploidyscreeningofhumanembryostoenhanceIVF
outcomes is based on sound principles. Multiple technologies have
demonstrated that aneuploidy is common in preimplantation embryos
and involves monosomies and trisomies of all 22 autosomes as well as
the sex chromosomes (Fragouli et al., 2009; Vanneste et al., 2009;
Johnson et al., 2010; Treff et al., 2010). The prevalence of abnormalities
at the time of antenatal screening and in live born infants is dramatically
lowerthanthatfoundinembryos(reviewedinHassoldandHunt,2001).
The difference in these rates is reﬂective of the fact that aneuploid
embryos either fail to implant or arrest in their development during
the early phases of gestation in most cases. A small residual clinical
risk remains for ongoing aneuploid gestations (typically involving triso-
mies or monosomy X) which may remain viable and are ultimately live
born. If embryos could be accurately screened prior to transfer, those
which are aneuploid could be eliminated. By transferring only euploid
embryos, the diminutionin reproductiveefﬁciencyattributable toaneu-
ploidy might be reduced or eliminated. Clinical beneﬁts should include
higher implantation rates, lower pregnancy loss rates and a reduction
in the risk for delivery of an anomalous infant.
Unfortunately, clinical results with preimplantation genetic screening
(PGS) for aneuploidy have not demonstrated the theoretical improve-
mentswhichwereanticipated(Staessenetal.,2004,2008;Mastenbroek
etal.,2007;Hardarsonetal.,2008;Schoolcraftetal.,2009).Infact,every
randomized clinical trial performed to date has failed to demonstrate
improved outcomes on an intent-to-treat basis. Putative explanations
for this clinical failure have included mosaicism, self-correction of aneu-
ploidywithintheembryo,evaluationofaverylimitednumberofchromo-
somes with the most commonly used technology—ﬂuorescence in situ
hybridization (FISH), an adverse impact of embryo biopsy which over-
whelms any positive inﬂuence gained by aneuploidy screening and
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Committee of the Society for Assisted Reproductive Technology and
PracticeCommitteeoftheAmericanSocietyforReproductiveMedicine,
2007; Anderson and Pickering, 2008; American Congress of Obstetri-
cians and Gynecologists Committee Opinion, 2009).
While all of these factors mayhavecontributed to the lackof success
of FISH-based aneuploidyscreening, the mostconcerning arethe issues
relating to technical accuracy. Evaluation of a single blastomere is chal-
lenging. Unfortunately, direct evaluation of the reliability of FISH on
human embryonic blastomeres has not been done. Scientists have
madegreateffortstooptimizeFISHinthissettingandhaveprovidedesti-
matesoferrorrates(e.g.Collsetal.,2007).Thesecalculationsrequirea
variety of assumptions. When multiple cells are evaluated from a single
embryo and differing results are attained, it is difﬁcult to know whether
those differences should be attributed to genuine mosaicism, or if they
reﬂect a failure of the technique to provide reproducible results.
Some investigators have addressed this question by taking embryos
which were diagnosed as aneuploid following biopsy and FISH evalu-
ation of a blastomere on Day 3 and then re-evaluating the embryo
at the blastocyst stage. In fact, non-concurrence rates following an
abnormal Day 3 FISH result and re-analysis at the blastocyst stage
on Day 5 of development are substantial (Magli et al., 2000; Li
et al., 2005; Munne et al., 2005; Fragouli et al., 2008; Barbash-Hazan
et al., 2009). Euploidy rates in these embryos previously designated
as abnormal may be as high as 71% (Munne et al., 2005).
Interpretingthedatafromre-evaluationstudiesisfurthercomplicated
by the use of differing deﬁnitions for ‘concurrence’. If the blastocyst is
aneuploid but has a differentchromosomal abnormality than thatident-
iﬁed on the original Day 3 biopsy, should the original diagnosis be con-
sidered concurrent or non-concurrent? If the standard is purely
clinical, then the detection of aneuploidy in both samples would lead
tothesameclinicaldesignation(non-viable)anditispossibletoconsider
thattheoriginalclinicaldiagnosiswasassignedcorrectlyeventhoughthe
technical results clearly differed. This is an extremely low standard and
would not be suitable for evaluating the reliability of a technique.
One option for evaluating the precision of aneuploidy screening
would be to analyze multiple cells from the same embryos with two
different technologies. For example, a cleavage-stage embryo which
has arrested and been discarded for research could be dispersed
into individual cells and then randomly assigned to analysis by either
FISH or another method such as copy number analysis by SNP
microarray-based 24 chromosome aneuploidy screening (Treff et al.,
2010). While some mosaicism is almost inevitable, the paired nature
of the comparison would control for its impact on the results obtained
by each technique. In other words, mosaicism should be equally
common with both techniques. Any consistent disparity in results
with one relative to the other would strongly suggest that the tech-
niques are not providing equivalent results. This study is designed to
evaluate the consistency in aneuploidy assessment using two aneu-
ploidy screening techniques.
Materials and Methods
Population
Supernumerary embryos were donated to research by infertile patients
participating in the IVF program. Embryos which arrested in extended
culture were considered for the study. Embryos on Day 5 of in vitro devel-
opment which had failed to progress through compaction to form either a
morulae or blastocyst were selected for the study. As such, these embryos
were not considered viable or suitable for cryopreservation for future clini-
cal use. All patients gave informed consent to have their non-viable
embryos donated to the research program by following an IRB approved
protocol.
Experimental design
The goal of this research was to determine the consistency in diagnostic
results obtained with FISH and microarray-based aneuploidy screening.
To that end, it was necessary to evaluate and compare multiple cells
from the same embryo. The experimental design is outlined in Fig. 1.
Embryos which had failed to compact but which had eight or more cells
on Day 5 were speciﬁcally selected for study. The cells all needed to be
intact, with a visible nucleus, and no evidence of multinucleation in any
cell at any point during embryonic development.
The selected embryos were biopsied into individual cells. It was then
necessary to randomly assign the cells from that individual embryo to
either FISH or microarray-based analysis. As such, each embryo had its
own unique randomization table. Using that table, the blastomeres from
each embryo were randomly assigned to FISH or microarray analysis.
Cells which were randomized to FISH-based analysis were ﬁxed one cell
per slide to avoid bias when interpreting the FISH results. Blastomeres ran-
domized to microarray-based analysis were placed into individual PCR
tubes for cell lysis.
While there was a unique randomization table for each individual
embryo to make certain that the cells were distributed approximately
equally between the two study groups, the numbers used to label the
glass slides and lysis buffer tubes were assigned from a separate single
large randomization table. This was essential to assure blinding of the lab-
oratory team. It was not possible for the laboratory scientists to know
which slides or tubes came from the same embryos. They were also
unaware of how many cells came from each embryo or even how many
embryos were being evaluated in the study.
Assays
The isolated blastomeres which were randomized to undergo FISH analy-
sis were ﬁxed, one cell to a glass slide. Each cell had been pre-incubated in
a hypotonic solution and ﬁxed using 3:1 methanol:acetic acid solution.
Two rounds of FISH were performed on ﬁxed blastomeres using probes
speciﬁc for chromosomes 13, 15, 16, 17, 18, 21, 22, X and Y (Vysis,
Downer’s Grove, IL, USA). The slides were analyzed using an automated
Olympus BX61 ﬂuorescence microscope (Center Valley, PA, USA). The
images were captured using Cytovision probe software (Applied Imaging
Corp, San Jose, CA, USA). Reconﬁrmation of inconclusive results was con-
ducted as previously described (Colls et al., 2007).
Blastomeres which were randomized to undergo microarray-based
analysis were placed into individual reaction tubes containing lysis buffer.
Each then underwent microarray-based copy number analysis for whole
chromosome aneuploidy as previously described (Treff et al., 2010).
This microarray technology previously demonstrated 98.6% accuracy in
a randomized blinded analysis of single cells from cell lines with whole
chromosome aneuploidies previously identiﬁed by conventional cytoge-
netics (Treff et al., 2010). Accuracy per chromosome was greater than
99%. However, we have not validated this single cell microarray technol-
ogy for identiﬁcation of segmental aneuploidy and therefore it could not be
used for this purpose in the present study. Brieﬂy, whole genomic ampli-
ﬁcation was conducted according to the recommended protocol beginning
with library preparation (GenomePlex WGA4, Sigma Aldrich, St. Louis,
Missouri). Whole genome ampliﬁed DNA was then puriﬁed using the
584 Treff et al.GenElute PCR Puriﬁcation Kit as recommended (Sigma Aldrich). Two-
hundred and ﬁfty nanograms of puriﬁed DNA were then processed
through the NspI GeneChip Mapping 262 K microarray as recommended
by the manufacturer (Affymetrix, Santa Clara, CA, USA). Aneuploidy
screening was performed by copy number analysis of the microarray
data using the Copy Number Analysis Tool (CNAT) version 4.0.1 (Affy-
metrix). The microarray data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus and are accessible
through GEO Series accession number GSE20 975 (http://www.ncbi.
nlm.nih.gov/geo).
Statistics
Samples were analyzed and a genetic result assigned. The fact that the
samples undergoing FISH were evaluated for nine chromosomes while
those undergoing microarray analysis were evaluated for 24 chromosomes
(all twenty two autosomes, and X and Y) provides an unequal opportunity
to identify aneuploidy and thus to have discrepant results. In particular,
when comparing the consistency of genetic diagnoses, the difference in
the number of chromosomes being evaluated would provide an advantage
for the FISH group where there would be only nine chances to obtain a
different result.
The results obtained from each technology for each individual cell were
then collated by embryo for comparison. Since both techniques will
occasionally fail to provide an interpretable result, the no-result rates
were compared using a Pearson’s chi square test for concurrence. Follow-
ing this comparison, those cells which failed to provide a genetic diagnosis
were excluded from further consideration.
The genetic diagnoses for each technology were reviewed for each indi-
vidual embryo. If all the genetic diagnoses were the same with a particular
technology then there would be perfect concurrence of results. In con-
trast, if any of the diagnoses using a particular technology were different,
then that embryo was designated as being mosaic according to that tech-
nology. The number of unique genetic diagnoses made by FISH was com-
pared with the number made by microarray using a paired Student’s t-test.
The prevalence of mosaicism identiﬁed by each method was compared
using a Fisher exact test.
Results
One hundred and sixty cells were evaluated from thirteen arrested
cleavage-stage embryos (median of 13 cells per embryo; range 9–
16). No cells were lost during the biopsy process. Seventy ﬁve cells
were randomized to FISH-based analysis with the remaining 85 cells
designated to undergo evaluation by microarray. The number of inter-
pretable results obtained for each technique for each embryo is pre-
sented in Table I. Microarray analyses produced interpretable results
in 82 of 85 cells (96%). In contrast, FISH analyses produced interpret-
able results in only 62 of 75 cells (83%). This difference was statistically
signiﬁcant (P ¼ 0.004).
The speciﬁc genetic diagnoses obtained with each technique for
each cell are presented in Table II. Eight of the 13 embryos (62%)
were diagnosed as uniformly diploid (all cells) by microarray. The
remaining 5 embryos displayed at least one aneuploid cell by microar-
ray; 2 embryos were mosaic aneuploid, 2 were mosaic diploid/aneu-
ploid, and 1 was a uniformly aneuploid embryo. In contrast, 10 of the
13 embryos were diagnosed as mosaic diploid/aneuploid by FISH
including the same 8 embryos that were diagnosed as uniformly
diploid by microarray. The remaining 3 embryos were diagnosed as
mosaic aneuploid by FISH. The prevalence of mosaicism was therefore
100% in the FISH group. In contrast, the prevalence of mosaicism was
31% in the microarray group, and was signiﬁcantly lower than the FISH
group (P ¼ 0.0005).
Perhaps more important than the overall prevalence of mosaicism is
the number of unique genetic diagnoses which would have been
assigned to each embryo. In the FISH group, there were almost as
many different genetic diagnoses as there were cells analyzed. For
example, embryo number seven had 6 cells evaluable and received
ﬁve different genetic diagnoses. The mean number of unique genetic
diagnoses assigned to each individual embryo was 3.2+0.2 by FISH
Figure 1 Blastomeres from the same cleavage-stage embryos were
biopsied into individual cells and randomized to analysis by either
FISH or microarray. Blastomeres from multiple embryos were ran-
domized together so that the embryo speciﬁc origin of each blasto-
mere was blinded. The paired randomized design controls for true
mosaicism and the blinded analysis avoids bias in interpretation
from knowledge of each blastomere’s embryo of origin.
Microarray-based aneuploidy screening is more consistent than FISH 585and 1.3+0.2 by microarray. Microarray displayed signiﬁcantly fewer
unique genetic diagnoses (P , 0.0001) despite evaluating more
chromosomes per cell (24 by microarray compared with 9 by
FISH), and evaluating more cells per embryo.
Discussion
The phenomenon of chromosomal mosaicism in the developing
human embryo has complicated the interpretation of inconsistent
aneuploidy diagnoses of multiple samples from the same embryo.
Indeed, there are at least two interpretations of inconsistencies
observed after analysis of multiple blastomeres from within the
same embryo. One interpretation is that true mosaicism, which
likely occurs as a result of errors in chromosome segregation during
mitotic cell division, was present in the embryo. Indeed, mosaicism
represents the primary source of variation that has been used to
explain the inconsistencies observed by FISH-based aneuploidy
screening. However, a largely overlooked interpretation is that the
observed inconsistencies are due to the FISH technique itself.
Although high rates of mosaicism have been found by other
methods, including conventional comparative genomic hybridization
(CGH) (Voullaire et al., 2000; Wells and Delhanty, 2000), and array
CGH combined with a multiple displacement ampliﬁcation based
SNP microarray analysis (Vanneste et al., 2009), no previous studies
have been performed using the present study design (where blasto-
meres from the same embryos were randomized to blinded analysis
by two independent technologies). Until such a study design has
been implemented to evaluate other technologies, it will remain
unclear as to whether previous estimates of the prevalence of
mitotic aneuploidy made by these other technologies are based on
true mosaicism or technical limitations.
Randomization of cells within the same embryo and blinded analysis
by two different methods provided a unique opportunity to isolate the
putative individual contributions made by true mosaicism and technical
limitations to the inconsistency in aneuploidy diagnoses. Blinded analy-
sis is a critical component since knowledge of whether speciﬁc blasto-
meres belong to the same embryo can signiﬁcantly bias interpretation
of the results. For example, interpretation of a blastomere that would
otherwise be difﬁcult to make might be inﬂuenced by a diagnosis made
for another blastomere from the same embryo. Although previous
reports describing FISH-based diagnosis of aneuploidy have elected
to attribute inconsistencies primarily to mosaicism, the present
study indicates that the most likely explanation is inconsistency of
the technique itself.
First, the microarray process was signiﬁcantly more reliable for pro-
ducing an interpretable result (P ¼ 0.004). This could be due to the
speciﬁc method of sample processing for microarray-based analyses
which is independent of cell spreading or ﬁxation known to be an
unreliable process that is required for FISH. It could also be related
to the nature of the blastomeres in this study, in that they were
derived from arrested embryos rather than developmentally normal
embryos. The present study found that 13 blastomeres (17%) failed
to provide an interpretable FISH result; 8 were anucleated, 2 were
lost during ﬁxation, and 3 were not analyzable (covered in debris).
Although this rate of failure is considerably higher than the approxi-
mately 6% failure rate recently reported by the ESHRE PGD consor-
tium for blastomeres derived from developmentally normal
cleavage-stage embryos (Goossens et al., 2009), it is below that of a
previously reported FISH analysis of 719 arrested cleavage-stage
embryos, where an overall failure rate of 23% was found; 106 cells
were anucleated, 17 were broken during biopsy, 25 were lost
during ﬁxation, and 17 were not analyzable (Munne et al., 1994).
.............................................................. ..............................................................
.............................................................................................................................................................................................
Table I Blastomeresthatwere randomized from 13cleavage-stageembryosand producedinterpretable results byeither
FISH or microarray.
Embryo No. Total No. of
Randomized Cells
FISH Microarray
No. of Cells
Randomized
No. of Interpretable
Results
No. of Cells
Randomized
No. of Interpretable
Results
11 4 7 5 7 6
21 4 7 7 7 6
31 0 4 3 6 6
41 5 7 5 8 8
51 1 5 5 6 5
69 4 4 5 5
71 6 8 6 8 8
81 0 4 2 6 6
91 3 6 5 7 7
10 15 7 5 8 8
11 13 6 6 7 7
12 9 4 3 5 5
13 11 6 6 5 5
Total No. of
Reliability
160 75 62 (83%) 85 82 (96%
a)
aIndicates microarray interpretation of the results is signiﬁcantly more reliable than FISH (P ¼ 0.004).
586 Treff et al.Microarray-based aneuploidy screening also displayed signiﬁcantly
higher consistency in diagnosis for blastomeres randomized from the
same embryos that underwent FISH-based analysis (P , 0.0001).
FISH predicted a rate of mosaicism of 100%, while microarray pre-
dicted a signiﬁcantly lower rate of 31% (P ¼ 0.0005). As a result of
the randomized and paired design, it was not possible that cells with
true mosaicism were assigned to the FISH analysis group only. More-
over, since microarray analyses were more reliable for providing an
interpretable result, there were more blastomeres analyzed per
embryo by microarray than by FISH, thus providing a larger opportu-
nity for true mosaicism to impact observations made by microarray.
Microarray analysis also included diagnosis of all 24 chromosomes,
......................................................................................... ................................................................................
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Table II Numberof unique diagnoses made by FISH and microarray from multiple blastomeres randomized, blinded and
paired after biopsy from the same embryos.
Embryo
No.
FISH Result Microarray Result
Results (no. of cells) No.
Unique
Results
Interpretation Results (no. of
cells)
No.
Unique
Results
Interpretation
1 Dip female(3) 2 Mosaic Diploid/Aneuploid 46,XX(6) 1 Uniformly Diploid
+18 female(2)
2 Dip male(5) 3 Mosaic Diploid/Aneuploid 46,XY(6) 1 Uniformly Diploid
218 male(1)
215,217,218,221 male(1)
3 Dip male(1) 3 Mosaic Diploid/Aneuploid 46,XY(6) 1 Uniformly Diploid
213 male(1)
+13,216,221 male(1)
4 Dip male(3) 3 Mosaic Diploid/Aneuploid 46,XY(8) 1 Uniformly Diploid
216 male(1)
213 male(1)
5 Dip male(2) 4 Mosaic Diploid/Aneuploid 46,XY(5) 1 Uniformly Diploid
tet male(1)
XXY(1)
+13,+18 male(1)
6 +22 female(2) 3 Mosaic Aneuploid 46,XX,219,+22(4) 2 Mosaic Aneuploid
complex aneuploid(1) 45,XX,219(1)
tet female(1)
7 Dip female(2) 5 Mosaic Diploid/Aneuploid 46,XX(8) 1 Uniformly Diploid
213,215 female(1)
222,+18 female(1)
213,216,222 female(1)
218,XXX(1)
8 222 female(1) 2 Mosaic Aneuploid 45,XX,222(6) 1 Uniformly Aneuploid
222,XXX(1)
9 Dip female(3) 3 Mosaic Diploid/Aneuploid 46,XX(7) 1 Uniformly Diploid
216 female(1)
complex aneuploid(1)
10 Dip female(2) 4 Mosaic Diploid/Aneuploid 46,XX(7) 2 Mosaic Diploid/Aneuploid
213,217 female(1) 47,XX,+18(1)
213 female(1)
213,216,218 female(1)
11 Dip female(3) 4 Mosaic Diploid/Aneuploid 46,XX(2) 3 Mosaic Diploid/Aneuploid
218,222 female(1) 45,XX,217(4)
213,218,221 female(1) 47,XX,+19(1)
complex aneuploid(1)
12 complex aneuploid(1) 3 Mosaic Aneuploid Complex aneuploid(5) 1 Mosaic Aneuploid
XYYY(1)
216,217,218 male(1)
13 Dip female(4) 3 Mosaic Diploid/Aneuploid 46,XX(5) 1 Uniformly Diploid
+13 female(1)
215,217,XXY(1)
Mean Mean
3.2+0.2 1.3+0.2
a
aIndicates signiﬁcantly fewer unique diagnoses by microarray compared with FISH for the same embryos (P , 0.0001). dip, diploid; tet, tetraploid.
Microarray-based aneuploidy screening is more consistent than FISH 587while FISH analysis only included 9 chromosomes, again providing a
larger opportunity for true mosaicism to impact the observations
made by microarray-based analysis.
Together with previous studies which indicate poor predictive value
of cleavage-stage FISH for aneuploidy in morphologically normal blasto-
cysts (Li et al., 2005; Munne et al., 2005; Fragouli et al., 2008; Barbash-
Hazan et al., 2009), and the absence of clinical beneﬁt observed in many
randomized controlled trials, it is becoming clear that FISH-based tech-
nology is inadequate for the diagnosis of aneuploidy in human embryos.
One important implication of the current study is that previous
interpretation of FISH-based analysis of the origin of human aneuploidy
may be incorrect. For example, in this study, a signiﬁcantly larger pro-
portion of embryos would have been assigned as having mitotic error
when estimated by FISH-based analysis (100%) compared with
microarray-based analysis (31%). Therefore, aneuploidy screening tech-
nologies with better consistency may provide better estimates of the
origin of aneuploidy in human embryos that are more in line with the
primarily observed maternal meiotic origins of aneuploidy in products
of conception (reviewed in Hassold et al., 2007).
Despite the growing evidence that FISH-based aneuploidy screening
does not work, the concept of improving outcomes by aneuploidy
screening should not be considered invalid. Indeed, new comprehen-
sive technologies such as SNP microarray-based 24 chromosome
aneuploidy screening may result in the realization of the expected clini-
cal beneﬁt. However, development and validation of these new tech-
nologies should be held to a higher standard than FISH. These
standards should include demonstration of preclinical accuracy, con-
sistency, and reliability. In addition, completion of randomized trials
with class I strength of evidence for clinical beneﬁt, and experimentally
demonstrating acceptable risk of clinical implementation (i.e. a negli-
gible impact of biopsy), should be required before any new aneuploidy
screening technologies are offered as a clinical routine (reviewed in
Scott and Treff, 2010).
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